New York, NY -- (SBWIRE) -- 01/16/2014 -- PennyStockChronicle covers the breadth of the markets, from NASDAQ, NYSE, AMEX, ETF, Penny Stocks, Emerging Markets, activities at the Fed and more. PennyStockChronicle brings you the most vibrant coverage of following stocks: Sonus Networks, Inc (NASDAQ:SONS), Oxygen Biotherapeutics, Inc (NASDAQ:OXBT), Cerus Corporation (NASDAQ:CERS), Oncothyreon Inc (USA) (NASDAQ:ONTY)
Sonus Networks, Inc (NASDAQ:SONS) showed a volume of 1.24 million shares by the end of last trade whereas the average volume of the stock remained 1.28 million shares. The stock opened the session at $2.91 but then moved to $3.08. At that price, the stock showed a positive performance of 5.48%. Sonus Networks, Inc. (Sonus) is a provider of networked solutions for communications service providers e.g., telecommunications, wireless and cable service providers and enterprises to help them advance, protect and unify their communications and improve collaboration. Its products include session border controllers, Session Initiation Protocol (SIP) session management servers,
Will SONS Continue To Move Higher? Find Out Here
Oxygen Biotherapeutics, Inc (NASDAQ:OXBT) opened the session at $6.40 and closed the session at $6.55. The stock showed a positive performance of 2.02% in previous trading session. Oxygen Biotherapeutics, Inc. (Oxygen Biotherapeutics) is engaged in the business of developing biotechnology products with a focus on oxygen delivery to tissue. As of April 30, 2011, the Company is developing Oxycyte, a systemic perfluorcarbon (PFC), product. It has developed a family of perfluorocarbon-based oxygen carriers for use in personal care, topical wound healing,
For How Long OXBT will fight for Profitability? Read This Trend Analysis report
Cerus Corporation (NASDAQ:CERS) opened the session at $7.38 and closed the session at $7.00. The stock showed a negative performance of -5.28% in previous trading session. Traded with volume of 1.22 million shares in the prior session and the average volume of the stock remained 481,147.00 shares. The beta of the stock remained 2.06. Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on the Company's technology for controlling biological replication, is designed to inactivate blood-borne pathogens in donated blood components intended for transfusion.
Why Should Investors Buy CERS After the Recent Fall? Just Go Here and Find Out
Oncothyreon Inc (USA) (NASDAQ:ONTY) the stock advanced 3.40% and finished the session at $2.13. Traded with volume of 1.22 million shares in the prior session and the average volume of the stock remained 686,517.00 shares. The beta of the stock remained 1.54. Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company’s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins.
Will ONTY Continue To Move Higher? Find Out Here
Penny Stock Chronicle is comprised of a team of vetted penny stock traders who’ve been trading since 2008 & have developed the skills needed to trade for consistent profits.
PLEASE NOTE WELL: The employees of PennyStockChronicle.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockChronicle.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockChronicle.com is not offering securities for sale. Neither PennyStockChronicle.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockChronicle.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockChronicle.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer at: http://pennystockchronicle.com/disclaimer
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)